Moderna Statistics
Share Statistics
Moderna has 384.82M shares outstanding. The number of shares has increased by 0.82% in one year.
| Shares Outstanding | 384.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 343.14M |
| Failed to Deliver (FTD) Shares | 115 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 34.38M, so 8.94% of the outstanding shares have been sold short.
| Short Interest | 34.38M |
| Short % of Shares Out | 8.94% |
| Short % of Float | 10.02% |
| Short Ratio (days to cover) | 7.59 |
Valuation Ratios
The PE ratio is -8.06 and the forward PE ratio is -5.
| PE Ratio | -8.06 |
| Forward PE | -5 |
| PS Ratio | 5.55 |
| Forward PS | 4.8 |
| PB Ratio | 2.74 |
| P/FCF Ratio | -9.93 |
| PEG Ratio | n/a |
Enterprise Valuation
Moderna Inc. has an Enterprise Value (EV) of 36.33B.
| EV / Earnings | -7.71 |
| EV / Sales | 5.3 |
| EV / EBITDA | -11.06 |
| EV / EBIT | -8.57 |
| EV / FCF | -9.5 |
Financial Position
The company has a current ratio of 3.42, with a Debt / Equity ratio of 0.
| Current Ratio | 3.42 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -111.55 |
Financial Efficiency
Return on equity (ROE) is -0.34% and return on capital (ROIC) is -33.58%.
| Return on Equity (ROE) | -0.34% |
| Return on Assets (ROA) | -0.26% |
| Return on Capital (ROIC) | -33.58% |
| Revenue Per Employee | 1.22M |
| Profits Per Employee | -841.79K |
| Employee Count | 5.60K |
| Asset Turnover | 0.37 |
| Inventory Turnover | 23.23 |
Taxes
| Income Tax | 772.00M |
| Effective Tax Rate | -0.2 |
Stock Price Statistics
The stock price has increased by -51.37% in the last 52 weeks. The beta is 1.69, so Moderna 's price volatility has been higher than the market average.
| Beta | 1.69 |
| 52-Week Price Change | -51.37% |
| 50-Day Moving Average | 48.97 |
| 200-Day Moving Average | 92.98 |
| Relative Strength Index (RSI) | 45.02 |
| Average Volume (20 Days) | 7.06M |
Income Statement
In the last 12 months, Moderna had revenue of $6.85B and earned -$4.71B in profits. Earnings per share was $-12.34.
| Revenue | 6.85B |
| Gross Profit | 2.15B |
| Operating Income | -4.24B |
| Net Income | -4.71B |
| EBITDA | -3.28B |
| EBIT | -4.24B |
| Earnings Per Share (EPS) | -12.34 |
Balance Sheet
The company has $2.91B in cash and $1.24B in debt, giving a net cash position of $1.66B.
| Cash & Cash Equivalents | 2.91B |
| Total Debt | 1.24B |
| Net Cash | 1.66B |
| Retained Earnings | 13.61B |
| Total Assets | 15.80B |
| Working Capital | 7.46B |
Cash Flow
In the last 12 months, operating cash flow was -$3.12B and capital expenditures -$707.00M, giving a free cash flow of -$3.83B.
| Operating Cash Flow | -3.12B |
| Capital Expenditures | -707.00M |
| Free Cash Flow | -3.83B |
| FCF Per Share | -10.01 |
Margins
Gross margin is 31.47%, with operating and profit margins of -61.9% and -68.84%.
| Gross Margin | 31.47% |
| Operating Margin | -61.9% |
| Pretax Margin | -57.56% |
| Profit Margin | -68.84% |
| EBITDA Margin | -47.94% |
| EBIT Margin | -61.9% |
| FCF Margin | -55.86% |
Dividends & Yields
MRNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -29.5% |
| FCF Yield | -23.77% |
Analyst Forecast
The average price target for MRNA is $69, which is 65% higher than the current price. The consensus rating is "Hold".
| Price Target | $69 |
| Price Target Difference | 65% |
| Analyst Consensus | Hold |
| Analyst Count | 17 |
Scores
| Altman Z-Score | 3.93 |
| Piotroski F-Score | 2 |